GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » Cash Receipts from Fees and Commissions

OncoZenge AB (FRA:8LY) Cash Receipts from Fees and Commissions


View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


OncoZenge AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » Cash Receipts from Fees and Commissions
Traded in Other Exchanges
Address
Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.